COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia Article Swipe
Andrew R. Branagan
,
Matthew Lei
,
Jenny S. Maron
,
Andrew J. Yee
,
Elizabeth OʼDonnell
,
Jorge J. Castillo
,
Noopur Raje
,
Steven P. Treon
,
Catherine Flynn
,
Clifton C. Mo
,
Omar Nadeem
,
Paul G. Richardson
,
Cristina Panaroni
,
Kirsten Meid
,
Zachary S. Bernstein
,
Ronan A Lyons
,
Zachary R. Hunter
,
Maria Luisa Guerrera
,
Marilyn T. Gammon
,
Kathleen J. Lively
,
Lisette Packer
,
Matthew Waterman
,
R. Gallagher
,
Boris Juleg
,
Galit Alter
,
Shayna Sarosiek
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1182/blood-2021-154089
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1182/blood-2021-154089
BACKGROUND: Multiple myeloma (MM) and Waldenström macroglobulinemia (WM) are associated with significant immunoparesis. Based on the ongoing COVID-19 pandemic, there is an urgent need to understand whether patients are able to mount a sufficient response to COVID-19 vaccines. METHODS: MM and WM patients are vaccinated with mRNA-1273 (Moderna), BNT162b2 mRNA (Pfizer/BioNTech), or JNJ-78436735 (Johnson & Johnson) in a prospective clinical trial. Primary endpoint is SARS-CoV-2 spike protein (S) antibody (Ab) detection 28 days after final vaccination. Secondary endpoints include functional serologic assessments and T-cell responses at 28 days, 6 months, 9 months, and 12 months following vaccination. S Abs were detected by Elecsys assay (Roche Diagnostics), with ³ 0.80 U/mL defined as positive and titers > 250 U/mL considered stronger correlates of neutralization. SARS-CoV-2 wildtype and variant S-specific Ab isotypes and FcγR binding profiles were quantified by custom Luminex assay. Antibody-dependent neutrophil and cellular phagocytosis (ADNP and ADCP) were assessed using flow cytometry. RESULTS: To date 141 patients have been enrolled, 137 (91 MM and 46 WM) of whom had an S Ab assessment. Median Ab titer was 178.0 (IQR, 16.10-1166.0) for MM and 3.92 (IQR, 0-278.9) for WM. S Ab response rate was 91% (83/91) in MM and 56% (27/46) in WM. However, responses achieving S Ab >250 U/mL were 47.3% (43/91) in MM and 26.1% (12/46) in WM. In patients ³75 years, responses >250 u/mL were 13.3% (2/15; p<0.05). Vaccine-specific S Ab responses >250 u/mL following mRNA-1273, BNT162b2, and JNJ-78436735 were 67.6% (23/34; p<0.05), 38.3% (18/47; p=NS), and 20% (2/10; p=NS) in MM and 50.0% (8/16; p<0.05), 14.8% (4/27; p<0.05), and 0% (0/3; p=NS) in WM. Among MM patients with progressive disease, S Ab response >250 u/mL occurred in 30% (6/20) as opposed to 55.6% (30/54) for VGPR+ (p<0.05). MM patients having autologous stem cell transplant within 12 months demonstrated 100% (5/5; p<0.05) S Ab responses. For MM patients actively receiving an anti-CD38 monoclonal Ab or an immunomodulatory drug, S Ab response occurred in 38.9% (14/36; p=NS) and 50.9% (28/55; p<0.05). Among WM patients, S Ab responses >250 U/mL occurred in 63.6% (7/11; p<0.05) previously untreated; 0% (0/9; p<0.05) who received rituximab within 12 months; 10% (2/20); p<0.05) on an active Bruton Tyrosine Kinase (BTK) inhibitor; and 20% (3/15; p=NS) who received other therapies. Functional Ab studies were performed on 14 MM patients, 14 WM, patients, and 14 healthy donors (HD) (Figure 1). All patients were assessed 28 days following their final vaccination and myeloma patients had an additional assessment 28 days following initial vaccination. MM and WM patients demonstrated less IGG1 and IGG3 S Ab production than HD. MM patients showed increased IgA and IgM S Ab production as well as increased FcgR2A binding following a second vaccine in contrast to HD. Both ADNP and ADCP were reduced in MM and WM patients. MM patients demonstrated improved ADCP in SARS-CoV-2 variants B.1.351, B.1.117, and P.1 versus wildtype (p<0.05). CONCLUSIONS: We report the first known evidence of impaired functional humoral responses following COVID-19 vaccines in patients with MM and WM. Overall, WM patients showed more severe impairment of COVID-19 S Ab responses. Most previously untreated WM patients achieved S Ab responses, however the most significant reduction in S Ab responses were seen in WM patients who received rituximab within 12 months or active BTK inhibitors. For MM patients, being in disease remission associated with improved S Ab response. Among MM and WM patients, age ³75 years associated with significantly lower rates and vaccination with MRNA-1273 (Moderna) elicited significantly higher S Ab response rates than other vaccines. A defect in ADNP and more profound defect in ADCP suggests overall compromised opsinophagocytic activity among MM and WM patients. Data comparing first and second vaccine responses in MM patients, suggest less efficient class switching to IGG as well as incomplete maturation of their FcgR2A binding profiles but normal maturation of FcgR3A. Interestingly, ADCP was improved in several emerging SARS-CoV-2 variants. T-cell studies are pending and will be updated. Further understanding of the immunological response to COVID19 vaccination is needed to clarify patients risks, and necessity for booster or alternative protective measures against COVID-19. Figure 1 Figure 1. Disclosures Branagan: Adaptive Biotechnologies: Consultancy; BeiGene: Consultancy; CSL Behring: Consultancy; Karyopharm: Consultancy; Pharmacyclics: Consultancy; Sanofi Genzyme: Consultancy. Lei: AbbVie: Honoraria; Epizyme: Honoraria; Fresenius Kabi: Consultancy; Intervention Insights: Consultancy. Yee: Amgen: Consultancy; Bristol Myer Squibb: Consultancy; Adaptive: Consultancy; GSK: Consultancy; Janssen: Consultancy; Oncopeptides: Consultancy; Sanofi: Consultancy; Takeda: Consultancy; Karyopharm: Consultancy. O'Donnell: Adaptive: Consultancy; Bristol Myer Squibb: Consultancy; Janssen: Consultancy; Karyopharm: Consultancy; Onocopeptide: Consultancy; Takeda: Consultancy. Castillo: Abbvie: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy; Roche: Consultancy; TG Therapeutics: Research Funding. Raje: Celgene, Amgen, Bluebird Bio, Janssen, Caribou, and BMS: Other. Treon: BeiGene: Consultancy, Research Funding; Eli Lily: Research Funding; Abbvie/Pharmacyclics: Consultancy, Research Funding. Mo: GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy; Eli Lilly: Consultancy; Janssen: Honoraria; Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Nadeem: Takeda: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees. Richardson: Oncopeptides: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Karyopharm: Consultancy, Research Funding; Protocol Intelligence: Consultancy; Janssen: Consultancy; Sanofi: Consultancy; Secura Bio: Consultancy; GlaxoSmithKline: Consultancy; Regeneron: Consultancy; AstraZeneca: Consultancy; AbbVie: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding. Juleg: Leyden Labs: Current Employment; Amsterdam: Current Employment; Netherlands: Current Employment.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1182/blood-2021-154089
- OA Status
- green
- Cited By
- 2
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4200121427
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4200121427Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1182/blood-2021-154089Digital Object Identifier
- Title
-
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström MacroglobulinemiaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-11-05Full publication date if available
- Authors
-
Andrew R. Branagan, Matthew Lei, Jenny S. Maron, Andrew J. Yee, Elizabeth OʼDonnell, Jorge J. Castillo, Noopur Raje, Steven P. Treon, Catherine Flynn, Clifton C. Mo, Omar Nadeem, Paul G. Richardson, Cristina Panaroni, Kirsten Meid, Zachary S. Bernstein, Ronan A Lyons, Zachary R. Hunter, Maria Luisa Guerrera, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Matthew Waterman, R. Gallagher, Boris Juleg, Galit Alter, Shayna SarosiekList of authors in order
- Landing page
-
https://doi.org/10.1182/blood-2021-154089Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/8701550Direct OA link when available
- Concepts
-
Medicine, Waldenstrom macroglobulinemia, Surrogate endpoint, Internal medicine, Clinical endpoint, Gastroenterology, Antibody, Titer, Macroglobulinemia, Immunology, Vaccination, Multiple myeloma, Clinical trial, LymphomaTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 1, 2022: 1Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4200121427 |
|---|---|
| doi | https://doi.org/10.1182/blood-2021-154089 |
| ids.doi | https://doi.org/10.1182/blood-2021-154089 |
| ids.openalex | https://openalex.org/W4200121427 |
| fwci | 0.1462874 |
| type | article |
| title | COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia |
| biblio.issue | Supplement 1 |
| biblio.volume | 138 |
| biblio.last_page | 3801 |
| biblio.first_page | 3801 |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9987999796867371 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T10649 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9858999848365784 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2720 |
| topics[1].subfield.display_name | Hematology |
| topics[1].display_name | Multiple Myeloma Research and Treatments |
| topics[2].id | https://openalex.org/T11157 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9848999977111816 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2716 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Chronic Lymphocytic Leukemia Research |
| is_xpac | False |
| apc_list.value | 5000 |
| apc_list.currency | USD |
| apc_list.value_usd | 5000 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8182488679885864 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2781038049 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6340495347976685 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1778287 |
| concepts[1].display_name | Waldenstrom macroglobulinemia |
| concepts[2].id | https://openalex.org/C141341695 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5742695331573486 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2368661 |
| concepts[2].display_name | Surrogate endpoint |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5370985269546509 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C203092338 |
| concepts[4].level | 3 |
| concepts[4].score | 0.478861540555954 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[4].display_name | Clinical endpoint |
| concepts[5].id | https://openalex.org/C90924648 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4669293761253357 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[5].display_name | Gastroenterology |
| concepts[6].id | https://openalex.org/C159654299 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4621056020259857 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[6].display_name | Antibody |
| concepts[7].id | https://openalex.org/C32611913 |
| concepts[7].level | 3 |
| concepts[7].score | 0.461779922246933 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[7].display_name | Titer |
| concepts[8].id | https://openalex.org/C2776391228 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4567287564277649 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q4118092 |
| concepts[8].display_name | Macroglobulinemia |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.4504106044769287 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C22070199 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4251110553741455 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q192995 |
| concepts[10].display_name | Vaccination |
| concepts[11].id | https://openalex.org/C2776364478 |
| concepts[11].level | 2 |
| concepts[11].score | 0.34867438673973083 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[11].display_name | Multiple myeloma |
| concepts[12].id | https://openalex.org/C535046627 |
| concepts[12].level | 2 |
| concepts[12].score | 0.30393415689468384 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[12].display_name | Clinical trial |
| concepts[13].id | https://openalex.org/C2779338263 |
| concepts[13].level | 2 |
| concepts[13].score | 0.08587366342544556 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[13].display_name | Lymphoma |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8182488679885864 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/waldenstrom-macroglobulinemia |
| keywords[1].score | 0.6340495347976685 |
| keywords[1].display_name | Waldenstrom macroglobulinemia |
| keywords[2].id | https://openalex.org/keywords/surrogate-endpoint |
| keywords[2].score | 0.5742695331573486 |
| keywords[2].display_name | Surrogate endpoint |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.5370985269546509 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[4].score | 0.478861540555954 |
| keywords[4].display_name | Clinical endpoint |
| keywords[5].id | https://openalex.org/keywords/gastroenterology |
| keywords[5].score | 0.4669293761253357 |
| keywords[5].display_name | Gastroenterology |
| keywords[6].id | https://openalex.org/keywords/antibody |
| keywords[6].score | 0.4621056020259857 |
| keywords[6].display_name | Antibody |
| keywords[7].id | https://openalex.org/keywords/titer |
| keywords[7].score | 0.461779922246933 |
| keywords[7].display_name | Titer |
| keywords[8].id | https://openalex.org/keywords/macroglobulinemia |
| keywords[8].score | 0.4567287564277649 |
| keywords[8].display_name | Macroglobulinemia |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.4504106044769287 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/vaccination |
| keywords[10].score | 0.4251110553741455 |
| keywords[10].display_name | Vaccination |
| keywords[11].id | https://openalex.org/keywords/multiple-myeloma |
| keywords[11].score | 0.34867438673973083 |
| keywords[11].display_name | Multiple myeloma |
| keywords[12].id | https://openalex.org/keywords/clinical-trial |
| keywords[12].score | 0.30393415689468384 |
| keywords[12].display_name | Clinical trial |
| keywords[13].id | https://openalex.org/keywords/lymphoma |
| keywords[13].score | 0.08587366342544556 |
| keywords[13].display_name | Lymphoma |
| language | en |
| locations[0].id | doi:10.1182/blood-2021-154089 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S200071133 |
| locations[0].source.issn | 0006-4971, 1528-0020 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0006-4971 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Blood |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Blood |
| locations[0].landing_page_url | https://doi.org/10.1182/blood-2021-154089 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:8701550 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Blood |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8701550 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5032177345 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3868-9267 |
| authorships[0].author.display_name | Andrew R. Branagan |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[0].affiliations[0].raw_affiliation_string | Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[0].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[0].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Massachusetts General Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Andrew R. Branagan |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[1].author.id | https://openalex.org/A5042921399 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-5348-6065 |
| authorships[1].author.display_name | Matthew Lei |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[1].affiliations[0].raw_affiliation_string | Pharmacy Department, Massachusetts General Hospital, Boston, MA |
| authorships[1].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[1].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Massachusetts General Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Matthew M Lei |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Pharmacy Department, Massachusetts General Hospital, Boston, MA |
| authorships[2].author.id | https://openalex.org/A5044188951 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-5945-4945 |
| authorships[2].author.display_name | Jenny S. Maron |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[2].affiliations[0].raw_affiliation_string | Ragon Institute at Harvard University, Cambridge, |
| authorships[2].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[2].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Jenny S Maron |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Ragon Institute at Harvard University, Cambridge, |
| authorships[3].author.id | https://openalex.org/A5055089118 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3623-7491 |
| authorships[3].author.display_name | Andrew J. Yee |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[3].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[3].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[3].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Massachusetts General Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Andrew J Yee |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[4].author.id | https://openalex.org/A5055832458 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4042-1526 |
| authorships[4].author.display_name | Elizabeth OʼDonnell |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[4].affiliations[0].raw_affiliation_string | Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[4].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[4].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Massachusetts General Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Elizabeth O'Donnell |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[5].author.id | https://openalex.org/A5024726033 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9490-7532 |
| authorships[5].author.display_name | Jorge J. Castillo |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[5].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[5].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[5].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Jorge J. Castillo |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[6].author.id | https://openalex.org/A5052048627 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-3066-1275 |
| authorships[6].author.display_name | Noopur Raje |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[6].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[6].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[6].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Massachusetts General Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Noopur S. Raje |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[7].author.id | https://openalex.org/A5081299017 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-6393-6154 |
| authorships[7].author.display_name | Steven P. Treon |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[7].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[7].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[7].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Steven P Treon |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[8].author.id | https://openalex.org/A5055168389 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-7645-3469 |
| authorships[8].author.display_name | Catherine Flynn |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[8].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[8].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[8].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Catherine A Flynn |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[9].author.id | https://openalex.org/A5023403446 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-8190-2484 |
| authorships[9].author.display_name | Clifton C. Mo |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA |
| authorships[9].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[9].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[9].institutions[0].type | facility |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Clifton C. Mo |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA |
| authorships[10].author.id | https://openalex.org/A5052163068 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-4124-4277 |
| authorships[10].author.display_name | Omar Nadeem |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA |
| authorships[10].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[10].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Omar Nadeem |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA |
| authorships[11].author.id | https://openalex.org/A5043526996 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-7426-8865 |
| authorships[11].author.display_name | Paul G. Richardson |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA |
| authorships[11].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[11].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Paul G. Richardson |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA |
| authorships[12].author.id | https://openalex.org/A5029810145 |
| authorships[12].author.orcid | https://orcid.org/0009-0007-4724-3260 |
| authorships[12].author.display_name | Cristina Panaroni |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[12].affiliations[0].raw_affiliation_string | Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[12].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[12].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Massachusetts General Hospital |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Cristina Panaroni |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[13].author.id | https://openalex.org/A5070629260 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Kirsten Meid |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[13].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[13].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[13].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[13].institutions[0].type | facility |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Kirsten Meid |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[14].author.id | https://openalex.org/A5017202417 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-2269-8695 |
| authorships[14].author.display_name | Zachary S. Bernstein |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[14].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[14].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[14].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Massachusetts General Hospital |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Zachary S. Bernstein |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[15].author.id | https://openalex.org/A5086157485 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-5225-000X |
| authorships[15].author.display_name | Ronan A Lyons |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[15].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[15].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[15].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Massachusetts General Hospital |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Rebecca T. Lyons |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[16].author.id | https://openalex.org/A5026121534 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-1689-1691 |
| authorships[16].author.display_name | Zachary R. Hunter |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[16].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[16].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[16].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[16].institutions[0].type | facility |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Zachary R Hunter |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[17].author.id | https://openalex.org/A5062221935 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-0730-4678 |
| authorships[17].author.display_name | Maria Luisa Guerrera |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[17].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[17].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[17].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[17].institutions[0].type | facility |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Maria Luisa Guerrera |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[18].author.id | https://openalex.org/A5042842421 |
| authorships[18].author.orcid | |
| authorships[18].author.display_name | Marilyn T. Gammon |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[18].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[18].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[18].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Massachusetts General Hospital |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Marilyn T. Gammon |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[19].author.id | https://openalex.org/A5022030260 |
| authorships[19].author.orcid | |
| authorships[19].author.display_name | Kathleen J. Lively |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[19].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[19].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[19].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[19].institutions[0].type | healthcare |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Massachusetts General Hospital |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Kathleen J. Lively |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[20].author.id | https://openalex.org/A5089399997 |
| authorships[20].author.orcid | |
| authorships[20].author.display_name | Lisette Packer |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[20].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[20].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[20].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[20].institutions[0].type | healthcare |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | Massachusetts General Hospital |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Lisette Packer |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[21].author.id | https://openalex.org/A5058763934 |
| authorships[21].author.orcid | |
| authorships[21].author.display_name | Matthew Waterman |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[21].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[21].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[21].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[21].institutions[0].type | healthcare |
| authorships[21].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[21].institutions[0].country_code | US |
| authorships[21].institutions[0].display_name | Massachusetts General Hospital |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Matthew Waterman |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[22].author.id | https://openalex.org/A5010651718 |
| authorships[22].author.orcid | |
| authorships[22].author.display_name | R. Gallagher |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[22].affiliations[0].raw_affiliation_string | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[22].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[22].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[22].institutions[0].type | healthcare |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Massachusetts General Hospital |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Raquel Gallagher |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Massachusetts General Hospital Cancer Center, Boston, MA |
| authorships[23].author.id | https://openalex.org/A5038141348 |
| authorships[23].author.orcid | |
| authorships[23].author.display_name | Boris Juleg |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[23].affiliations[0].raw_affiliation_string | Ragon Institute at Harvard University, Cambridge, |
| authorships[23].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[23].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[23].institutions[0].type | healthcare |
| authorships[23].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Boris Juleg |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | Ragon Institute at Harvard University, Cambridge, |
| authorships[24].author.id | https://openalex.org/A5059371880 |
| authorships[24].author.orcid | https://orcid.org/0000-0002-7680-9215 |
| authorships[24].author.display_name | Galit Alter |
| authorships[24].countries | US |
| authorships[24].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[24].affiliations[0].raw_affiliation_string | Ragon Institute at Harvard University, Cambridge, |
| authorships[24].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[24].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[24].institutions[0].type | healthcare |
| authorships[24].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[24].institutions[0].country_code | US |
| authorships[24].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Galit Alter |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | Ragon Institute at Harvard University, Cambridge, |
| authorships[25].author.id | https://openalex.org/A5068329783 |
| authorships[25].author.orcid | https://orcid.org/0000-0002-0075-6735 |
| authorships[25].author.display_name | Shayna Sarosiek |
| authorships[25].countries | US |
| authorships[25].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[25].affiliations[0].raw_affiliation_string | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| authorships[25].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[25].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[25].institutions[0].type | facility |
| authorships[25].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[25].institutions[0].country_code | US |
| authorships[25].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[25].author_position | last |
| authorships[25].raw_author_name | Shayna Sarosiek |
| authorships[25].is_corresponding | False |
| authorships[25].raw_affiliation_strings | Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8701550 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9987999796867371 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W1972286386, https://openalex.org/W2040015650, https://openalex.org/W2981964593, https://openalex.org/W1988705540, https://openalex.org/W155378922, https://openalex.org/W2123323375, https://openalex.org/W3151943896, https://openalex.org/W2000967713, https://openalex.org/W2552000281, https://openalex.org/W2058941576 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2022 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 2 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:8701550 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Blood |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8701550 |
| primary_location.id | doi:10.1182/blood-2021-154089 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S200071133 |
| primary_location.source.issn | 0006-4971, 1528-0020 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0006-4971 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Blood |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Blood |
| primary_location.landing_page_url | https://doi.org/10.1182/blood-2021-154089 |
| publication_date | 2021-11-05 |
| publication_year | 2021 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 684 |
| abstract_inverted_index.6 | 89 |
| abstract_inverted_index.9 | 91 |
| abstract_inverted_index.A | 589 |
| abstract_inverted_index.S | 98, 172, 190, 207, 233, 275, 306, 322, 337, 427, 439, 512, 521, 530, 558, 582 |
| abstract_inverted_index.a | 33, 58, 449 |
| abstract_inverted_index.0% | 264, 349 |
| abstract_inverted_index.1. | 686 |
| abstract_inverted_index.12 | 94, 300, 356, 542 |
| abstract_inverted_index.14 | 383, 386, 390 |
| abstract_inverted_index.28 | 72, 87, 400, 413 |
| abstract_inverted_index.46 | 166 |
| abstract_inverted_index.Ab | 129, 173, 176, 191, 208, 234, 276, 307, 317, 323, 338, 378, 428, 440, 513, 522, 531, 559, 583 |
| abstract_inverted_index.In | 221 |
| abstract_inverted_index.MM | 40, 164, 183, 198, 215, 255, 270, 292, 310, 384, 418, 432, 463, 467, 500, 549, 562, 605, 617 |
| abstract_inverted_index.TG | 768 |
| abstract_inverted_index.To | 155 |
| abstract_inverted_index.WM | 42, 335, 420, 465, 504, 518, 536, 564, 607 |
| abstract_inverted_index.We | 483 |
| abstract_inverted_index.an | 22, 171, 314, 319, 362, 410, 800, 811, 830, 842, 854, 865, 876, 887, 899 |
| abstract_inverted_index.as | 112, 284, 442, 444, 626, 628 |
| abstract_inverted_index.at | 86 |
| abstract_inverted_index.be | 656 |
| abstract_inverted_index.by | 102, 137 |
| abstract_inverted_index.in | 57, 197, 202, 214, 219, 254, 267, 281, 326, 343, 452, 462, 472, 497, 529, 535, 552, 591, 597, 616, 645 |
| abstract_inverted_index.is | 21, 64, 667 |
| abstract_inverted_index.of | 122, 168, 489, 510, 631, 639, 660, 803, 814, 833, 845, 857, 868, 879, 890, 902 |
| abstract_inverted_index.on | 15, 361, 382, 799, 810, 829, 841, 853, 864, 875, 886, 898 |
| abstract_inverted_index.or | 52, 318, 544, 677, 805, 816, 835, 847, 859, 870, 881, 892, 904 |
| abstract_inverted_index.to | 25, 31, 36, 286, 454, 624, 664, 669 |
| abstract_inverted_index.³ | 108 |
| abstract_inverted_index.(91 | 163 |
| abstract_inverted_index.(S) | 68 |
| abstract_inverted_index.1). | 395 |
| abstract_inverted_index.10% | 358 |
| abstract_inverted_index.137 | 162 |
| abstract_inverted_index.141 | 157 |
| abstract_inverted_index.20% | 251, 370 |
| abstract_inverted_index.250 | 117 |
| abstract_inverted_index.30% | 282 |
| abstract_inverted_index.56% | 200 |
| abstract_inverted_index.91% | 195 |
| abstract_inverted_index.Abs | 99 |
| abstract_inverted_index.All | 396 |
| abstract_inverted_index.BTK | 546 |
| abstract_inverted_index.CSL | 694 |
| abstract_inverted_index.Eli | 787, 821 |
| abstract_inverted_index.For | 309, 548 |
| abstract_inverted_index.HD. | 431, 455 |
| abstract_inverted_index.IGG | 625 |
| abstract_inverted_index.IgA | 436 |
| abstract_inverted_index.IgM | 438 |
| abstract_inverted_index.Mo: | 795 |
| abstract_inverted_index.P.1 | 478 |
| abstract_inverted_index.WM) | 167 |
| abstract_inverted_index.WM, | 387 |
| abstract_inverted_index.WM. | 189, 203, 220, 268, 502 |
| abstract_inverted_index.age | 566 |
| abstract_inverted_index.and | 5, 41, 83, 93, 114, 126, 131, 143, 147, 165, 184, 199, 216, 241, 250, 256, 263, 330, 369, 389, 406, 419, 425, 437, 458, 464, 477, 501, 563, 574, 593, 606, 612, 654, 673, 779 |
| abstract_inverted_index.are | 9, 29, 44, 652 |
| abstract_inverted_index.but | 636 |
| abstract_inverted_index.for | 182, 188, 289, 675 |
| abstract_inverted_index.had | 170, 409 |
| abstract_inverted_index.the | 16, 485, 525, 661 |
| abstract_inverted_index.was | 178, 194, 643 |
| abstract_inverted_index.who | 352, 373, 538 |
| abstract_inverted_index.(Ab) | 70 |
| abstract_inverted_index.(HD) | 393 |
| abstract_inverted_index.(MM) | 4 |
| abstract_inverted_index.(WM) | 8 |
| abstract_inverted_index.0.80 | 109 |
| abstract_inverted_index.100% | 303 |
| abstract_inverted_index.3.92 | 185 |
| abstract_inverted_index.ADCP | 459, 471, 598, 642 |
| abstract_inverted_index.ADNP | 457, 592 |
| abstract_inverted_index.BMS: | 780, 808, 862 |
| abstract_inverted_index.Bio, | 776 |
| abstract_inverted_index.Bio: | 932 |
| abstract_inverted_index.Both | 456 |
| abstract_inverted_index.Data | 609 |
| abstract_inverted_index.GSK: | 724, 796, 884 |
| abstract_inverted_index.IGG1 | 424 |
| abstract_inverted_index.IGG3 | 426 |
| abstract_inverted_index.Jazz | 942 |
| abstract_inverted_index.Lei: | 704 |
| abstract_inverted_index.Most | 515 |
| abstract_inverted_index.Myer | 719, 740 |
| abstract_inverted_index.U/mL | 110, 118, 210, 341 |
| abstract_inverted_index.Yee: | 715 |
| abstract_inverted_index.able | 30 |
| abstract_inverted_index.been | 160 |
| abstract_inverted_index.cell | 297 |
| abstract_inverted_index.date | 156 |
| abstract_inverted_index.days | 73, 401, 414 |
| abstract_inverted_index.flow | 152 |
| abstract_inverted_index.have | 159 |
| abstract_inverted_index.less | 423, 620 |
| abstract_inverted_index.mRNA | 50 |
| abstract_inverted_index.more | 507, 594 |
| abstract_inverted_index.most | 526 |
| abstract_inverted_index.need | 24 |
| abstract_inverted_index.rate | 193 |
| abstract_inverted_index.seen | 534 |
| abstract_inverted_index.stem | 296 |
| abstract_inverted_index.than | 430, 586 |
| abstract_inverted_index.u/mL | 227, 237, 279 |
| abstract_inverted_index.well | 443, 627 |
| abstract_inverted_index.were | 100, 135, 149, 211, 228, 243, 380, 398, 460, 533 |
| abstract_inverted_index.whom | 169 |
| abstract_inverted_index.will | 655 |
| abstract_inverted_index.with | 11, 46, 107, 272, 499, 556, 570, 576 |
| abstract_inverted_index.³75 | 223, 567 |
| abstract_inverted_index.& | 55 |
| abstract_inverted_index.(0/3; | 265 |
| abstract_inverted_index.(0/9; | 350 |
| abstract_inverted_index.(5/5; | 304 |
| abstract_inverted_index.(ADNP | 146 |
| abstract_inverted_index.(BTK) | 367 |
| abstract_inverted_index.(IQR, | 180, 186 |
| abstract_inverted_index.13.3% | 229 |
| abstract_inverted_index.14.8% | 260 |
| abstract_inverted_index.178.0 | 179 |
| abstract_inverted_index.26.1% | 217 |
| abstract_inverted_index.38.3% | 247 |
| abstract_inverted_index.38.9% | 327 |
| abstract_inverted_index.47.3% | 212 |
| abstract_inverted_index.50.0% | 257 |
| abstract_inverted_index.50.9% | 331 |
| abstract_inverted_index.55.6% | 287 |
| abstract_inverted_index.63.6% | 344 |
| abstract_inverted_index.67.6% | 244 |
| abstract_inverted_index.ADCP) | 148 |
| abstract_inverted_index.Among | 269, 334, 561 |
| abstract_inverted_index.Based | 14 |
| abstract_inverted_index.Board | 802, 813, 832, 844, 856, 867, 878, 889, 901 |
| abstract_inverted_index.FcγR | 132 |
| abstract_inverted_index.Kabi: | 710 |
| abstract_inverted_index.Labs: | 949 |
| abstract_inverted_index.Lily: | 788 |
| abstract_inverted_index.Raje: | 772 |
| abstract_inverted_index.VGPR+ | 290 |
| abstract_inverted_index.after | 74 |
| abstract_inverted_index.among | 604 |
| abstract_inverted_index.assay | 104 |
| abstract_inverted_index.being | 551 |
| abstract_inverted_index.class | 622 |
| abstract_inverted_index.days, | 88 |
| abstract_inverted_index.drug, | 321 |
| abstract_inverted_index.final | 75, 404 |
| abstract_inverted_index.first | 486, 611 |
| abstract_inverted_index.known | 487 |
| abstract_inverted_index.lower | 572 |
| abstract_inverted_index.mount | 32 |
| abstract_inverted_index.other | 375, 587 |
| abstract_inverted_index.p=NS) | 253, 266, 329, 372 |
| abstract_inverted_index.rates | 573, 585 |
| abstract_inverted_index.spike | 66 |
| abstract_inverted_index.their | 403, 632 |
| abstract_inverted_index.there | 20 |
| abstract_inverted_index.titer | 177 |
| abstract_inverted_index.using | 151 |
| abstract_inverted_index.years | 568 |
| abstract_inverted_index.(2/10; | 252 |
| abstract_inverted_index.(2/15; | 230 |
| abstract_inverted_index.(3/15; | 371 |
| abstract_inverted_index.(4/27; | 261 |
| abstract_inverted_index.(6/20) | 283 |
| abstract_inverted_index.(7/11; | 345 |
| abstract_inverted_index.(8/16; | 258 |
| abstract_inverted_index.(Roche | 105 |
| abstract_inverted_index.Amgen, | 774 |
| abstract_inverted_index.Amgen: | 716 |
| abstract_inverted_index.Bruton | 364 |
| abstract_inverted_index.FcgR2A | 446, 633 |
| abstract_inverted_index.Figure | 683, 685 |
| abstract_inverted_index.Juleg: | 947 |
| abstract_inverted_index.Kinase | 366 |
| abstract_inverted_index.Leyden | 948 |
| abstract_inverted_index.Lilly: | 822 |
| abstract_inverted_index.Median | 175 |
| abstract_inverted_index.Other. | 781 |
| abstract_inverted_index.Roche: | 766 |
| abstract_inverted_index.Sanofi | 701 |
| abstract_inverted_index.Secura | 931 |
| abstract_inverted_index.T-cell | 84, 650 |
| abstract_inverted_index.Treon: | 782 |
| abstract_inverted_index.active | 363, 545 |
| abstract_inverted_index.assay. | 140 |
| abstract_inverted_index.custom | 138 |
| abstract_inverted_index.defect | 590, 596 |
| abstract_inverted_index.donors | 392 |
| abstract_inverted_index.having | 294 |
| abstract_inverted_index.higher | 581 |
| abstract_inverted_index.months | 95, 301, 543 |
| abstract_inverted_index.needed | 668 |
| abstract_inverted_index.normal | 637 |
| abstract_inverted_index.p=NS), | 249 |
| abstract_inverted_index.report | 484 |
| abstract_inverted_index.risks, | 672 |
| abstract_inverted_index.second | 450, 613 |
| abstract_inverted_index.severe | 508 |
| abstract_inverted_index.showed | 434, 506 |
| abstract_inverted_index.titers | 115 |
| abstract_inverted_index.trial. | 61 |
| abstract_inverted_index.urgent | 23 |
| abstract_inverted_index.versus | 479 |
| abstract_inverted_index.within | 299, 355, 541 |
| abstract_inverted_index.years, | 224 |
| abstract_inverted_index.(12/46) | 218 |
| abstract_inverted_index.(14/36; | 328 |
| abstract_inverted_index.(18/47; | 248 |
| abstract_inverted_index.(2/20); | 359 |
| abstract_inverted_index.(23/34; | 245 |
| abstract_inverted_index.(27/46) | 201 |
| abstract_inverted_index.(28/55; | 332 |
| abstract_inverted_index.(30/54) | 288 |
| abstract_inverted_index.(43/91) | 213 |
| abstract_inverted_index.(83/91) | 196 |
| abstract_inverted_index.(Figure | 394 |
| abstract_inverted_index.AbbVie: | 705, 940 |
| abstract_inverted_index.Abbvie: | 752 |
| abstract_inverted_index.Bristol | 718, 739 |
| abstract_inverted_index.COVID19 | 665 |
| abstract_inverted_index.Current | 950, 953, 956 |
| abstract_inverted_index.Elecsys | 103 |
| abstract_inverted_index.FcgR3A. | 640 |
| abstract_inverted_index.Further | 658 |
| abstract_inverted_index.Luminex | 139 |
| abstract_inverted_index.Nadeem: | 850 |
| abstract_inverted_index.Primary | 62 |
| abstract_inverted_index.Sanofi: | 730, 838, 929 |
| abstract_inverted_index.Squibb: | 720, 741 |
| abstract_inverted_index.Takeda: | 732, 749, 851, 916 |
| abstract_inverted_index.against | 681 |
| abstract_inverted_index.binding | 133, 447, 634 |
| abstract_inverted_index.booster | 676 |
| abstract_inverted_index.clarify | 670 |
| abstract_inverted_index.defined | 111 |
| abstract_inverted_index.disease | 553 |
| abstract_inverted_index.healthy | 391 |
| abstract_inverted_index.however | 524 |
| abstract_inverted_index.humoral | 492 |
| abstract_inverted_index.include | 79 |
| abstract_inverted_index.initial | 416 |
| abstract_inverted_index.months, | 90, 92 |
| abstract_inverted_index.months; | 357 |
| abstract_inverted_index.myeloma | 3, 407 |
| abstract_inverted_index.ongoing | 17 |
| abstract_inverted_index.opposed | 285 |
| abstract_inverted_index.overall | 600 |
| abstract_inverted_index.pending | 653 |
| abstract_inverted_index.protein | 67 |
| abstract_inverted_index.reduced | 461 |
| abstract_inverted_index.several | 646 |
| abstract_inverted_index.studies | 379, 651 |
| abstract_inverted_index.suggest | 619 |
| abstract_inverted_index.vaccine | 451, 614 |
| abstract_inverted_index.variant | 127 |
| abstract_inverted_index.whether | 27 |
| abstract_inverted_index.&gt; | 116 |
| abstract_inverted_index.(Johnson | 54 |
| abstract_inverted_index.0-278.9) | 187 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Adaptive | 689, 895 |
| abstract_inverted_index.B.1.117, | 476 |
| abstract_inverted_index.B.1.351, | 475 |
| abstract_inverted_index.BNT162b2 | 49 |
| abstract_inverted_index.Behring: | 695 |
| abstract_inverted_index.BeiGene: | 692, 756, 783 |
| abstract_inverted_index.Bluebird | 775 |
| abstract_inverted_index.COVID-19 | 18, 37, 495, 511 |
| abstract_inverted_index.Caribou, | 778 |
| abstract_inverted_index.Celgene, | 773 |
| abstract_inverted_index.Epizyme: | 707, 819 |
| abstract_inverted_index.Funding. | 771, 794, 946 |
| abstract_inverted_index.Funding; | 755, 759, 763, 786, 790, 911, 915, 919, 923 |
| abstract_inverted_index.Genzyme: | 702 |
| abstract_inverted_index.However, | 204 |
| abstract_inverted_index.Janssen, | 777 |
| abstract_inverted_index.Janssen: | 726, 743, 764, 824, 927 |
| abstract_inverted_index.Johnson) | 56 |
| abstract_inverted_index.METHODS: | 39 |
| abstract_inverted_index.Multiple | 2 |
| abstract_inverted_index.Overall, | 503 |
| abstract_inverted_index.Protocol | 924 |
| abstract_inverted_index.RESULTS: | 154 |
| abstract_inverted_index.Research | 754, 758, 762, 770, 785, 789, 793, 910, 914, 918, 922, 945 |
| abstract_inverted_index.Tyrosine | 365 |
| abstract_inverted_index.achieved | 520 |
| abstract_inverted_index.actively | 312 |
| abstract_inverted_index.activity | 603 |
| abstract_inverted_index.advisory | 806, 817, 836, 848, 860, 871, 882, 893, 905 |
| abstract_inverted_index.antibody | 69 |
| abstract_inverted_index.assessed | 150, 399 |
| abstract_inverted_index.cellular | 144 |
| abstract_inverted_index.clinical | 60 |
| abstract_inverted_index.contrast | 453 |
| abstract_inverted_index.detected | 101 |
| abstract_inverted_index.disease, | 274 |
| abstract_inverted_index.elicited | 579 |
| abstract_inverted_index.emerging | 647 |
| abstract_inverted_index.endpoint | 63 |
| abstract_inverted_index.entity's | 801, 812, 831, 843, 855, 866, 877, 888, 900 |
| abstract_inverted_index.evidence | 488 |
| abstract_inverted_index.impaired | 490 |
| abstract_inverted_index.improved | 470, 557, 644 |
| abstract_inverted_index.isotypes | 130 |
| abstract_inverted_index.measures | 680 |
| abstract_inverted_index.occurred | 280, 325, 342 |
| abstract_inverted_index.patients | 28, 43, 158, 222, 271, 293, 311, 397, 408, 421, 433, 468, 498, 505, 519, 537, 671 |
| abstract_inverted_index.positive | 113 |
| abstract_inverted_index.profiles | 134, 635 |
| abstract_inverted_index.profound | 595 |
| abstract_inverted_index.received | 353, 374, 539 |
| abstract_inverted_index.response | 35, 192, 277, 324, 584, 663 |
| abstract_inverted_index.stronger | 120 |
| abstract_inverted_index.suggests | 599 |
| abstract_inverted_index.updated. | 657 |
| abstract_inverted_index.vaccines | 496 |
| abstract_inverted_index.variants | 474 |
| abstract_inverted_index.wildtype | 125, 480 |
| abstract_inverted_index.(Moderna) | 578 |
| abstract_inverted_index.Adaptive: | 722, 737 |
| abstract_inverted_index.BNT162b2, | 240 |
| abstract_inverted_index.Branagan: | 688 |
| abstract_inverted_index.COVID-19. | 682 |
| abstract_inverted_index.Castillo: | 751 |
| abstract_inverted_index.Directors | 804, 815, 834, 846, 858, 869, 880, 891, 903 |
| abstract_inverted_index.Fresenius | 709 |
| abstract_inverted_index.Insights: | 713 |
| abstract_inverted_index.MRNA-1273 | 577 |
| abstract_inverted_index.Secondary | 77 |
| abstract_inverted_index.achieving | 206 |
| abstract_inverted_index.anti-CD38 | 315 |
| abstract_inverted_index.comparing | 610 |
| abstract_inverted_index.detection | 71 |
| abstract_inverted_index.efficient | 621 |
| abstract_inverted_index.endpoints | 78 |
| abstract_inverted_index.enrolled, | 161 |
| abstract_inverted_index.following | 96, 238, 402, 415, 448, 494 |
| abstract_inverted_index.increased | 435, 445 |
| abstract_inverted_index.mRNA-1273 | 47 |
| abstract_inverted_index.necessity | 674 |
| abstract_inverted_index.pandemic, | 19 |
| abstract_inverted_index.patients, | 336, 385, 388, 550, 565, 618 |
| abstract_inverted_index.patients. | 466, 608 |
| abstract_inverted_index.performed | 381 |
| abstract_inverted_index.receiving | 313 |
| abstract_inverted_index.reduction | 528 |
| abstract_inverted_index.remission | 554 |
| abstract_inverted_index.response. | 560 |
| abstract_inverted_index.responses | 85, 205, 225, 235, 339, 493, 532, 615 |
| abstract_inverted_index.rituximab | 354, 540 |
| abstract_inverted_index.serologic | 81 |
| abstract_inverted_index.switching | 623 |
| abstract_inverted_index.untreated | 517 |
| abstract_inverted_index.vaccines. | 38, 588 |
| abstract_inverted_index.variants. | 649 |
| abstract_inverted_index.(Moderna), | 48 |
| abstract_inverted_index.Amsterdam: | 952 |
| abstract_inverted_index.Functional | 377 |
| abstract_inverted_index.Honoraria, | 827, 839 |
| abstract_inverted_index.Honoraria; | 706, 708, 825 |
| abstract_inverted_index.Membership | 798, 809, 828, 840, 852, 863, 874, 885, 897 |
| abstract_inverted_index.O'Donnell: | 736 |
| abstract_inverted_index.Regeneron: | 936 |
| abstract_inverted_index.S-specific | 128 |
| abstract_inverted_index.SARS-CoV-2 | 65, 124, 473, 648 |
| abstract_inverted_index.additional | 411 |
| abstract_inverted_index.assessment | 412 |
| abstract_inverted_index.associated | 10, 555, 569 |
| abstract_inverted_index.autologous | 295 |
| abstract_inverted_index.considered | 119 |
| abstract_inverted_index.correlates | 121 |
| abstract_inverted_index.cytometry. | 153 |
| abstract_inverted_index.functional | 80, 491 |
| abstract_inverted_index.impairment | 509 |
| abstract_inverted_index.incomplete | 629 |
| abstract_inverted_index.inhibitor; | 368 |
| abstract_inverted_index.mRNA-1273, | 239 |
| abstract_inverted_index.maturation | 630, 638 |
| abstract_inverted_index.monoclonal | 316 |
| abstract_inverted_index.neutrophil | 142 |
| abstract_inverted_index.previously | 347, 516 |
| abstract_inverted_index.production | 429, 441 |
| abstract_inverted_index.protective | 679 |
| abstract_inverted_index.quantified | 136 |
| abstract_inverted_index.responses, | 523 |
| abstract_inverted_index.responses. | 308, 514 |
| abstract_inverted_index.sufficient | 34 |
| abstract_inverted_index.therapies. | 376 |
| abstract_inverted_index.transplant | 298 |
| abstract_inverted_index.understand | 26 |
| abstract_inverted_index.untreated; | 348 |
| abstract_inverted_index.vaccinated | 45 |
| abstract_inverted_index.&gt;250 | 209, 226, 236, 278, 340 |
| abstract_inverted_index.BACKGROUND: | 1 |
| abstract_inverted_index.Disclosures | 687 |
| abstract_inverted_index.Employment. | 957 |
| abstract_inverted_index.Employment; | 951, 954 |
| abstract_inverted_index.Karyopharm: | 697, 734, 745, 826, 873, 920 |
| abstract_inverted_index.Richardson: | 907 |
| abstract_inverted_index.alternative | 678 |
| abstract_inverted_index.assessment. | 174 |
| abstract_inverted_index.assessments | 82 |
| abstract_inverted_index.committees. | 849, 906 |
| abstract_inverted_index.committees; | 807, 818, 837, 861, 872, 883, 894 |
| abstract_inverted_index.compromised | 601 |
| abstract_inverted_index.inhibitors. | 547 |
| abstract_inverted_index.progressive | 273 |
| abstract_inverted_index.prospective | 59 |
| abstract_inverted_index.significant | 12, 527 |
| abstract_inverted_index.vaccination | 405, 575, 666 |
| abstract_inverted_index.AstraZeneca: | 938 |
| abstract_inverted_index.CONCLUSIONS: | 482 |
| abstract_inverted_index.Celgene/BMS: | 912 |
| abstract_inverted_index.Consultancy, | 753, 757, 761, 784, 792, 797, 909, 913, 917, 921, 944 |
| abstract_inverted_index.Consultancy. | 703, 714, 735, 750 |
| abstract_inverted_index.Consultancy; | 691, 693, 696, 698, 700, 711, 717, 721, 723, 725, 727, 729, 731, 733, 738, 742, 744, 746, 748, 765, 767, 820, 823, 926, 928, 930, 933, 935, 937, 939, 941 |
| abstract_inverted_index.Intervention | 712 |
| abstract_inverted_index.JNJ-78436735 | 53, 242 |
| abstract_inverted_index.Netherlands: | 955 |
| abstract_inverted_index.Waldenström | 6 |
| abstract_inverted_index.demonstrated | 302, 422, 469 |
| abstract_inverted_index.phagocytosis | 145 |
| abstract_inverted_index.vaccination. | 76, 97, 417 |
| abstract_inverted_index.16.10-1166.0) | 181 |
| abstract_inverted_index.Diagnostics), | 106 |
| abstract_inverted_index.Intelligence: | 925 |
| abstract_inverted_index.Oncopeptides: | 728, 908 |
| abstract_inverted_index.Onocopeptide: | 747 |
| abstract_inverted_index.Therapeutics: | 769 |
| abstract_inverted_index.immunological | 662 |
| abstract_inverted_index.significantly | 571, 580 |
| abstract_inverted_index.understanding | 659 |
| abstract_inverted_index.Interestingly, | 641 |
| abstract_inverted_index.Pharmacyclics: | 699, 760 |
| abstract_inverted_index.immunoparesis. | 13 |
| abstract_inverted_index.p&lt;0.05) | 305, 346, 351, 360 |
| abstract_inverted_index.neutralization. | 123 |
| abstract_inverted_index.p&lt;0.05), | 246, 259, 262 |
| abstract_inverted_index.p&lt;0.05). | 231, 333 |
| abstract_inverted_index.(p&lt;0.05). | 291, 481 |
| abstract_inverted_index.Biotechnologies: | 690, 896 |
| abstract_inverted_index.GlaxoSmithKline: | 934 |
| abstract_inverted_index.Pharmaceuticals: | 943 |
| abstract_inverted_index.Vaccine-specific | 232 |
| abstract_inverted_index.immunomodulatory | 320 |
| abstract_inverted_index.opsinophagocytic | 602 |
| abstract_inverted_index.macroglobulinemia | 7 |
| abstract_inverted_index.(Pfizer/BioNTech), | 51 |
| abstract_inverted_index.Antibody-dependent | 141 |
| abstract_inverted_index.Abbvie/Pharmacyclics: | 791 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 26 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8500000238418579 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.50488556 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |